# Jianying Zhou

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jianying-zhou/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,295 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 68 |
| i10-index | 265 |
| Last Known Institution | Jilin University |
| OpenAlex ID | https://openalex.org/A5052132950 |
| ORCID iD | https://orcid.org/0000-0002-8924-935X |
| Works | 820 |

## Researcher papers

Showing 12 of 18.

- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer](https://scholariq.org/papers/integrated-proteogenomic-characterization-of-human-high-grade-serous-ovarian/)
- [Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-pemetrexed-versus-chemotherapy-alone-in/)
- [Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial](https://scholariq.org/papers/gefitinib-plus-chemotherapy-versus-placebo-plus-chemotherapy-in-egfr-mutation/)
- [Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-vs-chemotherapy-alone-as-first-line-treatment-for/)
- [Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)](https://scholariq.org/papers/efficacy-and-safety-of-sintilimab-plus-pemetrexed-and-platinum-as-first-line/)
- [Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-a-predominantly-chinese-patient-population-with/)
- [Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)](https://scholariq.org/papers/sintilimab-plus-platinum-and-gemcitabine-as-first-line-treatment-for-advanced-or/)
- [AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations](https://scholariq.org/papers/aeneas-a-randomized-phase-iii-trial-of-aumolertinib-versus-gefitinib-as-first/)
- [Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-as-first-line-treatment-for-locally-advanced-or/)
- [Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)](https://scholariq.org/papers/anlotinib-as-a-third-line-therapy-in-patients-with-refractory-advanced-non-small/)
- [Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial](https://scholariq.org/papers/tepotinib-plus-gefitinib-in-patients-with-egfr-mutant-non-small-cell-lung-cancer/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Particle physics theoretical and experimental studies](https://scholariq.org/topics/particle-physics-theoretical-and-experimental-studies/)
- [Quantum Chromodynamics and Particle Interactions](https://scholariq.org/topics/quantum-chromodynamics-and-particle-interactions/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Jilin University](https://scholariq.org/institutions/jilin-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.